Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.4.2.30 (
PARP
)
13,611
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As an enzyme implicated in the stress response, we investigated poly(ADP-ribose) polymerase (
PARP
) in the response of GH3 rat
pituitary tumor
cells to oxidants. These cells are unusual in that they undergo rapid cell death (90 min) with low doses of the prooxidant, H2O2 (50-200 microm), whereas at higher doses (1 mm), death occurs some hours later (4-5 h). Measurement of
PARP
activity shows that low doses of H2O2 (50-200 microm) fail to increase the activity of
PARP
, whereas at 0.5 and 1 mm, the enzyme becomes activated. In parallel with the activation of
PARP
, cellular ATP concentrations fall at high H2O2 doses and the
PARP
inhibitors, 3-aminobenzamide and nicotinamide (NIC) partially prevent this fall. Using NIC to inhibit
PARP
activity, we show that treatment of cells with NIC before the addition of H2O2 (0.5-1 mm), results in rapid cell death (90 min). In contrast, prior exposure to H2O2 (0.5-1 mm) for 1 h, before withdrawal and exposure to 1 mm NIC, allows cell survival for many hours. These data suggest that
PARP
is involved in blocking rapid death of GH3 cells in response to oxidants. In contrast to other cell types tested here, in which inhibitor studies show that
PARP
is activated at low H2O2 doses and this decreases the extent of apoptosis, GH3 cells are unable to sufficiently activate
PARP
to prevent rapid cell death.
...
PMID:The role of poly (adenosine 5'-diphosphate-ribose) polymerase in the response of pituitary tumor cells to reactive oxygen species. 1556 35